Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
More News related to PGNX
- Progenics Announces Third Quarter 2009 Financial Results
- BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
- Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
- Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
- Needham Cuts Progenics (PGNX) to Hold Midday
Lazard Capital upgrades Progenics Pharmaceutical (Nasdaq: PGNX) from Hold to Buy.
To see more analyst ratings on PGNX Click Here.
Related Categories
UpgradesStocks Mentioned
+0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
